Efthymios Nikolaos Deliargyris's most recent trade in Cytosorbents Corp was a trade of 16,233 Common Stock done at an average price of $1 . Disclosure was reported to the exchange on Jan. 17, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cytosorbents Corp | Efthymios Nikolaos Deliargyris | Chief Medical Officer | 17 Jan 2025 | 16,233 | 403,025 (1%) | 0% | 1 | 16,233 | Common Stock | |
| Cytosorbents Corp | Efthymios Nikolaos Deliargyris | Chief Medical Officer | 17 Jan 2025 | 16,233 | 0 | - | - | Subscription Rights (right to buy) | ||
| Cytosorbents Corp | Efthymios Nikolaos Deliargyris | Chief Medical Officer | Other type of transaction at price $ 0.00 per share. | 17 Jan 2025 | 16,233 | 16,233 | - | - | Series A Right Warrants | |
| Cytosorbents Corp | Efthymios Nikolaos Deliargyris | Chief Medical Officer | Other type of transaction at price $ 0.00 per share. | 17 Jan 2025 | 16,233 | 16,233 | - | - | Series B Right Warrants | |
| Cytosorbents Corp | Efthymios Nikolaos Deliargyris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 100,000 | 100,000 | - | - | Stock Option (Right to Buy) | |
| Cytosorbents Corp | Efthymios Nikolaos Deliargyris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Oct 2024 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Cytosorbents Corp | Efthymios Nikolaos Deliargyris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2024 | 86,000 | 86,000 | - | - | Stock Option (Right to Buy) | |
| Cytosorbents Corp | Efthymios Nikolaos Deliargyris | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Apr 2024 | 61,000 | 409,433 (1%) | 0% | 0 | Common Stock |